vTv Therapeutics FY2023 net loss $20.3M; $51M PIPE funds Phase 3 cadisegliatin trial

vTv Therapeutics Inc.

Net loss attributable to shareholders $20.3M ($9.71/share) in FY2023 vs $19.2M ($9.98) in FY2022.
Cash $9.4M at Dec 31, 2023; subsequent $51M PIPE from institutional investors and JDRF T1D Fund closed Feb 28, 2024.
First Phase 3 trial of cadisegliatin for type 1 diabetes to enroll first patient in Q2 2024; top-line data expected by Q1 2026.
R&D expenses $13.6M in FY2023 (up 10% YoY); G&A expenses $11.9M (down 2% YoY).
Board reduced from 9 to 7; three new directors designated by new investors including Srinivas Akkaraju from Samsara.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

vTv Therapeutics Inc. reported financial results for the fiscal year ended December 31, 2023.

Period: the fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 13, 2024, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.